The authors assessed the efficacy and safety of antipsychotic drugs for treating delirium. They concluded that the use of some low-dose, short-term antipsychotic drugs is supported only by limited evidence, and that further research is required. The authors' conclusions follow from the evidence presented and appear reliable.
To evaluate the efficacy and safety of antipsychotic drugs for treating the symptoms of delirium.
Searching MEDLINE (January 1980 to July 2005 and the Cochrane Library were searched for articles published in English; the search terms were reported. The reference lists of retrieved articles were checked.
Study selection

Study designs of evaluations included in the review
Prospective studies that used standardised methods for diagnosing delirium and evaluating severity were eligible for inclusion. Studies of delirium associated with a specific state of intoxication or withdrawal were ineligible.
Specific interventions included in the review
Studies were eligible for inclusion if antipsychotic drugs were used to treat delirium. The included drugs were haloperidol, olanzapine, risperidone, quetiapine, chlorpromazine, lorazepam and mianserin. The mean daily dose ranged from 36 to 325 mg chlorpromazine equivalents. The duration of treatment varied. A few studies included pharmacologic cointerventions.
Participants included in the review
The included participants were patients from medical, surgical, cancer, intensive care unit and AIDS populations. The patients were aged from 19 to 92 years. Most of the patients were referred for psychiatry; some patients were recruited who had screened positive for delirium.
Outcomes assessed in the review
Studies that diagnosed delirium and assessed its severity using validated instruments were eligible for inclusion. The included outcomes were delirium severity, response to treatment, remission, time to improvement, and treatmentemergent serious and minor adverse events. Severity scales included the Delirium Rating Scale (DRS), the DRS 1998 revision, the Memorial Delirium Assessment Scale and the Delirium Index.
How were decisions on the relevance of primary studies made?
Two of the authors reviewed all of the retrieved studies. The decision to include a study was reached by consensus. The authors of primary studies were contacted for clarification when needed.
Assessment of study quality
The authors assessed study quality and variables that could affect delirium outcomes; positive or 'yes' scores for each variable were tabulated. Study quality variables included placebo-control, comparability of the groups at baseline, randomisation, double-blinding, intention-to-treat analyses, and adequate follow-up for drop-outs or withdrawals. Variables specific to delirium were inclusion of patients with dementia, comparison of delirium subtypes, exclusion or control of pharmacologic cointerventions, evaluation of side-effects, follow-up duration of at least 7 days, and daily assessment of delirium severity.
Data extraction
